Recommended dose modifications with XELODA monotherapy

Recommended dose modifications with XELODA monotherapy
*National Cancer Institute of Canada Common Toxicity Criteria were used except for HFS.

For dose modification recommendations when using XELODA plus docetaxel, consult the full prescribing information for XELODA.

FAQs   Print This Page   Send an E-card   Tell a Colleague   Bookmark This Page   Text Size   A A  A
Complete Product Information   Important Safety Information   Glossary   Site Map   Contact Us  
Roche Laboratories Inc. THIS SITE INTENDED FOR U.S. AUDIENCES ONLY
Copyright © 2004-2008 Roche Laboratories Inc. All rights reserved.
Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and PRIVACY Statement.
 
For more information about XELODA, contact your physician or other healthcare professional.